Nilotinib
Generic Details
Generic Name
Nilotinib
Other Names
- Tasigna
Drug Class
- Tyrosine Kinase Inhibitor (TKI)
Chemical Formula
C28H22F3N7O
Molecular Weight
529.51 g/mol
Mechanism of Action
- Inhibits BCR-ABL kinase activity
Indications
- Chronic Myeloid Leukemia (CML)
- Acute Lymphoblastic Leukemia (ALL)
Common Dosage Forms
- Capsules
Typical Dosage
- 300 mg twice daily
Pediatric Dosage
- Dosage based on body weight and age, under physician supervision
Geriatric Dosage
- Usually similar to adult dosage, individualized based on health status
Side Effects
- Nausea
- Fatigue
- Skin Rash
- Headache
- Low Blood Counts
- Liver Problems
Contraindications
- Hypersensitivity to nilotinib
- Strong CYP3A4 inhibitors/inducers
Pregnancy Category
- D - Positive evidence of risk
Lactation Safety
- Not recommended during breastfeeding, may harm the infant
Drug Interactions
- Strong CYP3A4 inducers/inhibitors
- Antacids
- St. John's Wort
Overdose Symptoms
- Nausea
- Vomiting
- Abdominal Pain
- Myelosuppression
Antidote for Overdose
- No specific antidote, manage symptoms and provide supportive care
Storage Conditions
- Store at room temperature (20-25°C)
- Protect from light and moisture
Pharmacokinetics
- Absorption: Variable, taken with food increases bioavailability
- Distribution: Extensively distributed, protein-bound
- Metabolism: Primarily hepatic via CYP3A4
- Excretion: Mainly feces
Precautions
- Cardiac monitoring due to QT prolongation risk
- Monitor liver function tests regularly
Warnings
- Risk of myelosuppression
- Sudden cardiac death potential with QT prolongation
Others
- Regular monitoring of blood counts and ECG recommended